GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Bharat Parenterals Ltd

Bharat Parenterals Q1 FY27 Results: Standalone Net Profit Rs. 365.71 Lakhs

RESULTS ▼ Concern Flagged MEDIUM RISK
📅 Filed on BSE: 05 Aug 2026, 05:49 PM IST  ·  BSE ID: 5a1570a3-97bb-41c3-965c-c2b5e7c2ed8c
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its first quarter financial results, with standalone profit but a consolidated loss, and scheduled its annual meeting.
🤖 AI Summary
  • Board approved unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.
  • Standalone Net Profit for Q1 FY27 stood at Rs. 365.71 Lakhs.
  • Consolidated Net Loss for Q1 FY27 was Rs. (356.33) Lakhs.
  • The 33rd Annual General Meeting is set for Saturday, September 19, 2026, via Video Conferencing.
  • Re-appointment of Mr. Hemang Shah as Executive Director for five years was approved, awaiting member sanction.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Standalone Revenue from operations (Q1 FY27)
5,550.10 Rs. In Lakhs
-41.19
Standalone Net Profit (Q1 FY27)
365.71 Rs. In Lakhs
-63.43
Consolidated Revenue from operations (Q1 FY27)
9,373.65 Rs. In Lakhs
-19.20
Consolidated Net Profit / (Loss) (Q1 FY27)
(356.33) Rs. In Lakhs
308.41
Standalone Basic EPS (Q1 FY27)
5.31 Rs.
-63.47
Standalone Total expenses (Q1 FY27)
5,162.35 Rs. In Lakhs
-37.50
🏢 How This Affects the Company
💰
Financial Impact
Standalone Net Profit for Q1 FY27 was Rs. 365.71 Lakhs, a decrease from Rs. 999.95 Lakhs in the prior comparable period. Consolidated Net Loss was Rs. (356.33) Lakhs, an increase from Rs. (87.25) Lakhs in the prior comparable period.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are required to review the notice for the 33rd Annual General Meeting scheduled for September 19, 2026, and participate in the e-voting process for resolutions including director re-appointment.
👤
Who Is Affected
All shareholders are affected by the financial performance, particularly by the decline in standalone net profit and widening consolidated net loss. Shareholders will also vote on the re-appointment of Mr. Hemang Shah as Executive Director.
🔍
Management Signal
The decision to approve Mr. Hemang Shah's re-appointment for five years signals management's intent for continuity in executive leadership, subject to member approval.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Annual General Meeting on September 19, 2026 — confirmation of director re-appointment.
Q2 FY27 Financial Results — review trend in standalone profit and consolidated loss.
Management Discussion and Analysis Report — details on factors impacting current quarter performance.
MEDIUM RISK Significant decline in standalone profit and substantial increase in consolidated net loss for the quarter.
💡 Investor Takeaway
Bharat Parenterals reported Q1 FY27 standalone Net Profit of Rs. 365.71 Lakhs, a 63.43% decrease from Rs. 999.95 Lakhs in Q1 FY26. Consolidated Net Loss widened to Rs. (356.33) Lakhs from Rs. (87.25) Lakhs in the prior comparable period.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone Net Profit for Q1 FY27 was Rs. 365.71 Lakhs, indicating continued profitability on a standalone basis.
  • Standalone EBITDA (excluding other income) to Revenue from operation ratio improved to 12.30% in Q1 FY27 from 0.06% in Q4 FY26.

⚠️ Concerns

  • Standalone Net Profit decreased by 63.43% to Rs. 365.71 Lakhs in Q1 FY27 from Rs. 999.95 Lakhs in Q1 FY26.
  • Consolidated Net Loss widened significantly to Rs. (356.33) Lakhs in Q1 FY27 from a loss of Rs. (87.25) Lakhs in Q1 FY26.
❓ Frequently Asked Questions
What was Bharat Parenterals' standalone net profit for the quarter ended June 30, 2026?
Bharat Parenterals reported a standalone Net Profit of Rs. 365.71 Lakhs for the quarter ended June 30, 2026.
What was Bharat Parenterals' consolidated net profit or loss for Q1 FY27?
Bharat Parenterals reported a consolidated Net Loss of Rs. (356.33) Lakhs for the quarter ended June 30, 2026.
When is Bharat Parenterals' 33rd Annual General Meeting scheduled?
The 33rd Annual General Meeting of Bharat Parenterals Limited is scheduled for Saturday, September 19, 2026.
Who was approved for re-appointment as an Executive Director by Bharat Parenterals' board?
Mr. Hemang Shah (DIN: 03024324) was approved for re-appointment as an Executive Director for five consecutive years, subject to member approval.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.